- Home
- VKTX vs ACAD Comparison
VKTX vs ACAD Comparison
Compare VKTX & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VKTX
- ACAD
- Stock Information
- Founded
- VKTX 2012
- ACAD 1993
- Country
- VKTX United States
- ACAD United States
- Employees
- VKTX N/A
- ACAD N/A
- Industry
- VKTX Biotechnology: Pharmaceutical Preparations
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- VKTX Health Care
- ACAD Health Care
- Exchange
- VKTX Nasdaq
- ACAD Nasdaq
- Market Cap
- VKTX 3.5B
- ACAD 4.0B
- IPO Year
- VKTX 2015
- ACAD 2004
- Fundamental
- Price
- VKTX $40.03
- ACAD $25.33
- Analyst Decision
- VKTX Strong Buy
- ACAD Buy
- Analyst Count
- VKTX 13
- ACAD 20
- Target Price
- VKTX $86.92
- ACAD $28.63
- AVG Volume (30 Days)
- VKTX 4.6M
- ACAD 1.7M
- Earning Date
- VKTX 07-23-2025
- ACAD 08-06-2025
- Dividend Yield
- VKTX N/A
- ACAD N/A
- EPS Growth
- VKTX N/A
- ACAD 615.00
- EPS
- VKTX N/A
- ACAD 1.33
- Revenue
- VKTX N/A
- ACAD $1,018,885,000.00
- Revenue This Year
- VKTX N/A
- ACAD $13.28
- Revenue Next Year
- VKTX $338.60
- ACAD $10.88
- P/E Ratio
- VKTX N/A
- ACAD $19.04
- Revenue Growth
- VKTX N/A
- ACAD 14.41
- 52 Week Low
- VKTX $18.92
- ACAD $13.40
- 52 Week High
- VKTX $81.73
- ACAD $25.88
- Technical
- Relative Strength Index (RSI)
- VKTX 69.97
- ACAD 65.86
- Support Level
- VKTX $39.35
- ACAD $24.43
- Resistance Level
- VKTX $41.68
- ACAD $25.88
- Average True Range (ATR)
- VKTX 2.06
- ACAD 0.80
- MACD
- VKTX 0.56
- ACAD 0.09
- Stochastic Oscillator
- VKTX 84.10
- ACAD 84.20
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.